Please assess the completion status of the following clinical trial:

Trial Title: GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* A signed and dated written informed consent prior to study participation~* Males or females of non-childbearing potential~* 40 to 80 years of age~* COPD diagnosis~* 10 pack-years history or greater of cigarette smoking~* Post-bronchodilator FEV1/FVC ratio of 0.70 or less~* Post-bronchodilator FEV1 of 35 to 70% of predicted normal~Exclusion Criteria:~* Asthma~* Other significant respiratory disorders besides COPD, including alpha-1 deficiency~* Previous lung resection surgery~* Use of oral steroids or antibiotics for a COPD exacerbation within 6 weeks of screening~* Hospitalization for COPD or pneumonia within 3 months of screening~* Any significant disease that would put subject at risk through study participation~* BMI greater than 35~* Pacemaker~* Significantly abnormal ECG, Holter, or clinical lab finding (including Hepatitis B or C)~* Cancer~* Allergy or hypersensitivity to anticholinergics or inhaler excipients~* Diseases that would contra-indicate the use of anticholinergics~* Use of oral corticosteroids within 6 weeks of screening~* Use of long-acting beta-agonists within 48 hours of screening~* Use of tiotropium within 14 days of screening~* Use of theophyllines or anti-leukotrienes within 48 hours of screening~* Use of short-acting bronchodilators within 4 to 6 hours of screening~* Use of investigational medicines within 30 days of screening~* Use of high dose inhaled corticosteroids~* Use of long-term oxygen therapy, CPAP or NIPPV~* Previous use of GSK573719

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium
- Arm 1 (Type: EXPERIMENTAL): GSK573719 1000mcg once daily
- Arm 2 (Type: EXPERIMENTAL): GSK573719 500mcg once daily
- Arm 3 (Type: EXPERIMENTAL): GSK573719 250mcg once daily
- Arm 4 (Type: EXPERIMENTAL): GSK573719 125mcg once daily
- Arm 5 (Type: EXPERIMENTAL): GSK573719 62.5 mcg once daily
- Arm 6 (Type: EXPERIMENTAL): GSK573719 250mcg twice daily
- Arm 7 (Type: EXPERIMENTAL): GSK573719 125mcg twice daily
- Arm 8 (Type: EXPERIMENTAL): GSK573719 62.5mcg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).